Anti-PD-1(2) Immunotherapy(2) anti-PD-L1(2) HBV(2) Viral hepatitis.(2) pharmacokinetics(1) volunteers.(1) 3CLpro(1) Treatment(1) RNA interference(1) Tolerability(1) antiviral protease inhibitor(1) Pharmacology(1) RNAi(1) pharmacokinetics.(1) Safety(1) hepatitis B(1) COVID-19(1) Viral hepatitis(1) Phase 1(1) PF-00835231(1)